1. Home
  2. EU vs FHTX Comparison

EU vs FHTX Comparison

Compare EU & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo enCore Energy Corp.

EU

enCore Energy Corp.

HOLD

Current Price

$2.66

Market Cap

464.5M

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$5.46

Market Cap

360.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EU
FHTX
Founded
2009
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Medicinal Chemicals and Botanical Products
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
464.5M
360.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
EU
FHTX
Price
$2.66
$5.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$4.00
$11.67
AVG Volume (30 Days)
3.6M
165.9K
Earning Date
03-02-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$44,142,000.00
$24,518,000.00
Revenue This Year
$17.41
$40.91
Revenue Next Year
$95.45
$11.87
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$2.95
52 Week High
$4.19
$6.95

Technical Indicators

Market Signals
Indicator
EU
FHTX
Relative Strength Index (RSI) 42.07 48.10
Support Level $2.60 $5.11
Resistance Level $2.90 $5.79
Average True Range (ATR) 0.24 0.34
MACD -0.07 -0.08
Stochastic Oscillator 5.56 38.20

Price Performance

Historical Comparison
EU
FHTX

About EU enCore Energy Corp.

enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: